Product Description
(Sourced from: https://www.benzinga.com/pressreleases/26/11/g62949361/eton-pharmaceuticals-reports-third-quarter-2026-financial-results)
Mechanisms of Action: CYP17A1 Inhibitor
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Harrow Health
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Prostate Cancer
Phase 0: Hemangioma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02349139 |
ASN001-101 | P1 |
Terminated |
Prostate Cancer |
2017-07-14 |
2023-02-26 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|
